Time Restricted Eating for Weight Management
- Conditions
- Obesity
- Interventions
- Other: Calorie restrictionOther: 8-hour Time restricted eating
- Registration Number
- NCT04692532
- Lead Sponsor
- University of Illinois at Chicago
- Brief Summary
A 12-month randomized, controlled, parallel-arm trial, divided into 2 consecutive periods: (1) 6-month weight loss period; and (2) 6-month weight maintenance, will be implemented. Adults with obesity will be randomized to 1 of 3 groups: (1) 8h-TRE, ad libitum food intake from 12pm to 8 pm, fasting from 8 pm to 12 pm daily, (2) CR, 25% energy restriction every day; or 3) control, ad libitum food intake daily, eating within more than 10 hours per day.
- Detailed Description
Time restricted eating (TRE) has become a popular weight loss regimen. The sudden rise in popularity of TRE is mostly likely due to is its sheer simplicity, and the fact that it does not require individuals to count calories in order to lose weight. Participants are simply asked to consume all food within a specified time frame and fast with energy free beverages for the remaining hours of the day. Evidence shows that when people with obesity limit their eating window to 6 to 8 hours per day, they naturally reduce energy intake by 350-500 calories. From a clinical standpoint, these findings are paramount. One of the main reasons for subject attrition with traditional dieting, i.e. daily calorie restriction (CR), is frustration with having to count calories every day. TRE regimens are able to side-step this requirement by allowing participants to simply "watch the clock" instead of monitoring calories, while still producing significant weight loss and metabolic health improvements. This feature of TRE has the potential to improve long-term adherence to the diet, and in turn produce lasting weight control in adults with obesity.
Accordingly, we conducted a one-year, randomized, controlled trial to compare the effects of late TRE (eating all food between 12:00 pm to 8:00 pm, without calorie counting), versus CR (25% energy restriction daily), and a control group eating over a period of 10 or more hours, on body weight and metabolic risk factors in a diverse group of American adults with obesity. We hypothesized that the TRE group would achieve greater weight loss, and experience more pronounced improvements in insulin sensitivity during the 6-month weight loss phase, compared to CR and control participants. We also hypothesized that the TRE group would better maintain their weight loss and sustain their improvements in insulin sensitivity during the 6-month weight maintenance phase, when compared to the CR and control participants.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Calorie restriction Calorie restriction 25% energy restriction every day 8-hour Time restricted eating 8-hour Time restricted eating Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
- Primary Outcome Measures
Name Time Method Change in body weight Measured at month 0, 6 and 12 Measured by an electronic scale
- Secondary Outcome Measures
Name Time Method Change in Blood pressure Measured at month 0, 6 and 12 Measured by a blood pressure cuff
Change in energy and nutrient intake Measured at month 0, 6 and 12 Measured by 7-day food record
Change in waist circumference Measured at month 0, 6 and 12 Measured by a measuring tape
Change in sleep quality Measured at month 0, 6 and 12 Measured by Pittsburgh Sleep Quality Index (PSQI), total score of 0-21. A PSQI total score greater than 5 indicates poor sleep quality.
Change in risk of sleep apnea Measured at month 0, 6 and 12 Measured by Berlin Questionnaire, measures the presence or absence of sleep apnea
Change in appetite Measured at month 0, 6 and 12 Measured by Visual analog scale (VAS). Scored from 0-100. Higher score means higher appetite.
Change in testosterone levels (ng/ml) Measured at month 0, 6 and 12 Measured by ELISA
Change in fat mass, lean mass, visceral fat mass Measured at month 0, 6 and 12 Measured by DXA
Change in bone mineral density Measured at month 0, 6 and 12 Measured by DXA
Change in Fasting glucose Measured at month 0, 6 and 12 Measured by a commercial lab (Medstar, IL)
Change in Fasting insulin Measured at month 0, 6 and 12 Measured by a commercial lab (Medstar, IL)
Change in Plasma lipids (LDL cholesterol, HDL cholesterol, triglycerides) Measured at month 0, 6 and 12 Measured by a commercial lab (Medstar, IL)
Change in estradiol levels (ng/ml) Measured at month 0, 6 and 12 Measured by ELISA
Change in mood Measured at month 0, 6 and 12 Measured by Beck Depression Inventory II (BDI-II) 25: total score 0-100. Higher scores mean worse outcome. Also measured by the Profile of Mood States (POMS)total score 0-100. Higher scores mean worse outcome.
Change in Insulin resistance Measured at month 0, 6 and 12 Measured by HOMA-IR
Change in Insulin sensitivity Measured at month 0, 6 and 12 Measured by QUICKI
Change in Heart rate Measured at month 0, 6 and 12 Measured by a blood pressure cuff
Change in sex hormone binding globulin (SHBG) levels (ng/ml) Measured at month 0, 6 and 12 Measured by ELISA
Change in the daily eating window Measured at month 0, 6 and 12 Measured by questionnaire (assesses the time the participant started and stopped eating each day)
Adverse events Measured at month 0, 6 and 12 Measured by questionnaire
Change in eating disorder symptoms Measured at month 0, 6 and 12 Measured by Multifactorial Assessment of Eating Disorders Symptoms (MAEDS), total score of 0-100, Higher scores mean worse outcome.
Change in HbA1c Measured at month 0, 6 and 12 Measured by a commercial lab (Medstar, IL)
Change in inflammatory markers (TNF-apha, IL-6, IL-10, IL-B, hs-CRP) Measured at month 0, 6 and 12 Measured by ELISA
Change in oxidative stress Measured at month 0, 6 and 12 Measured by ELISA
Change in physical activity (steps/d) Measured at month 0, 6 and 12 Measured by pedometer
Change in insomnia severity Measured at month 0, 6 and 12 Measured by Insomnia Severity Index (ISI), total score of 0-28. The total score for the ISI is interpreted as follows: no clinically significant insomnia (0-7), sub-threshold insomnia (8-14), moderate severity insomnia (15-21), and severe insomnia (22-28).
Change in quality of life Measured at month 0, 6 and 12 Measured by the Short Form Survey (SF-36): total score 0-100. Higher scores mean worse outcome.
Change in dehydroepiandrosterone (DHEA) levels (ng/ml) Measured at month 0, 6 and 12 Measured by ELISA
Change in progesterone levels (ng/ml) Measured at month 0, 6 and 12 Measured by ELISA
Trial Locations
- Locations (1)
University of Illinois Chicago
🇺🇸Chicago, Illinois, United States